GlassScriptPhysician profile
Melody Perlberg
NPI 1891045985
$12,706.93
in general payments reported to CMS, 2019-2025
24 companies · $2,252 in 2025
The $2,252 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,085 · 2022: $2,290 · 2023: $3,534 · 2024: $2,547 · 2025: $2,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,832 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,832.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,227.25 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,308.61 | 2023-2025 | Uzedy, Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $1,026.64 | 2023-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $887.83 | 2021-2025 | Trintellix |
| Lundbeck LLC | $857.14 | 2021-2025 | Rexulti, Brintellix |
| Tris Pharma INC | $774.50 | 2023-2025 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $757.37 | 2021-2025 | Rexulti, Nuedexta |
| Bausch Health US, LLC | $532.20 | 2021-2025 | Wellbutrin, Aplenzin |
| Axsome Therapeutics, INC. | $527.11 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $421.83 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $352.54 | 2022 | |
| Corium, LLC | $322.62 | 2022-2025 | Azstarys |
| Orexo US, INC. | $271.02 | 2021-2022 | |
| Almatica Pharma LLC | $270.52 | 2021-2025 | Loreev Xr |
| Neos Therapeutics, LP | $241.82 | 2023-2024 | Adzenys Xr-Odt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $221.01 | 2023-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $177.54 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $170.59 | 2025 | Fanapt |
| Lilly USA, LLC | $100.59 | 2022-2025 | Mounjaro, Zepbound |
| Idorsia Pharmaceuticals US INC | $99.53 | 2022-2024 | Quviviq |
| Eisai INC. | $95.01 | 2021-2022 | |
| Novo Nordisk INC | $23.32 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.34 | 2025 | Lifevest |
| Noven Therapeutics, LLC | $20.00 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melody Perlberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.